Bone Cancer

News alerts, weekly reports and conference planners

No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	doxorubicin hydrochloride Sensitive: A1 - Approval doxorubicin hydrochloride Sensitive : A1	doxorubicin hydrochloride Sensitive: A1 - Approval doxorubicin hydrochloride Sensitive : A1
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	methotrexate Sensitive: A1 - Approval methotrexate Sensitive : A1	methotrexate Sensitive: A1 - Approval methotrexate Sensitive : A1
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Chordoma	No biomarker	Chordoma	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
No biomarker	Chordoma	No biomarker	Chordoma	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
No biomarker	Chordoma	No biomarker	Chordoma	YD312 Sensitive: A2 - Guideline YD312 Sensitive : A2	YD312 Sensitive: A2 - Guideline YD312 Sensitive : A2
No biomarker	Chordoma	No biomarker	Chordoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Chordoma	No biomarker	Chordoma	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2
TMB-H	Chordoma	TMB-H	Chordoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
EGFR expression	Chordoma	EGFR expression	Chordoma	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	melphalan + busulfan Sensitive: A2 - Guideline melphalan + busulfan Sensitive : A2	melphalan + busulfan Sensitive: A2 - Guideline melphalan + busulfan Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	cyclophosphamide + ifosfamide + etoposide IV + topotecan Sensitive: A2 - Guideline cyclophosphamide + ifosfamide + etoposide IV + topotecan Sensitive : A2	cyclophosphamide + ifosfamide + etoposide IV + topotecan Sensitive: A2 - Guideline cyclophosphamide + ifosfamide + etoposide IV + topotecan Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	temozolomide + irinotecan Sensitive: A2 - Guideline temozolomide + irinotecan Sensitive : A2	temozolomide + irinotecan Sensitive: A2 - Guideline temozolomide + irinotecan Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	gemcitabine + docetaxel + cyclophosphamide Sensitive: A2 - Guideline gemcitabine + docetaxel + cyclophosphamide Sensitive : A2	gemcitabine + docetaxel + cyclophosphamide Sensitive: A2 - Guideline gemcitabine + docetaxel + cyclophosphamide Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	carboplatin + cyclophosphamide + etoposide IV Sensitive: A2 - Guideline carboplatin + cyclophosphamide + etoposide IV Sensitive : A2	carboplatin + cyclophosphamide + etoposide IV Sensitive: A2 - Guideline carboplatin + cyclophosphamide + etoposide IV Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	carboplatin + cyclophosphamide Sensitive: A2 - Guideline carboplatin + cyclophosphamide Sensitive : A2	carboplatin + cyclophosphamide Sensitive: A2 - Guideline carboplatin + cyclophosphamide Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	cyclophosphamide + etoposide IV Sensitive: A2 - Guideline cyclophosphamide + etoposide IV Sensitive : A2	cyclophosphamide + etoposide IV Sensitive: A2 - Guideline cyclophosphamide + etoposide IV Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	gemcitabine + docetaxel + ifosfamide Sensitive: A2 - Guideline gemcitabine + docetaxel + ifosfamide Sensitive : A2	gemcitabine + docetaxel + ifosfamide Sensitive: A2 - Guideline gemcitabine + docetaxel + ifosfamide Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	carboplatin + ifosfamide + etoposide IV Sensitive: A2 - Guideline carboplatin + ifosfamide + etoposide IV Sensitive : A2	carboplatin + ifosfamide + etoposide IV Sensitive: A2 - Guideline carboplatin + ifosfamide + etoposide IV Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	carboplatin + ifosfamide Sensitive: A2 - Guideline carboplatin + ifosfamide Sensitive : A2	carboplatin + ifosfamide Sensitive: A2 - Guideline carboplatin + ifosfamide Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate Sensitive : A2	cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	cisplatin + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline cisplatin + ifosfamide + pegylated liposomal doxorubicin Sensitive : A2	cisplatin + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline cisplatin + ifosfamide + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	ifosfamide + methotrexate + etoposide oral Sensitive: A2 - Guideline ifosfamide + methotrexate + etoposide oral Sensitive : A2	ifosfamide + methotrexate + etoposide oral Sensitive: A2 - Guideline ifosfamide + methotrexate + etoposide oral Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	sorafenib + everolimus Sensitive: A2 - Guideline sorafenib + everolimus Sensitive : A2	sorafenib + everolimus Sensitive: A2 - Guideline sorafenib + everolimus Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	gemcitabine + docetaxel Sensitive: A2 - Guideline gemcitabine + docetaxel Sensitive : A2	gemcitabine + docetaxel Sensitive: A2 - Guideline gemcitabine + docetaxel Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	cyclophosphamide + topotecan Sensitive: A2 - Guideline cyclophosphamide + topotecan Sensitive : A2	cyclophosphamide + topotecan Sensitive: A2 - Guideline cyclophosphamide + topotecan Sensitive : A2

Bone Cancer

Associations(117)

Associations
(117)